Intratumoral PD-1+Vγ1+ cells display an exhaustion program similar to that of αβ T cells, can be derepressed by checkpoint inhibitors and are predictive of the response to anti-PD-1 in patients with melanoma, specifically those with low levels of neoantigens.

See Davies et al.

A cell-therapy platform based on dendritic cell progenitors that express immunostimulatory cytokines has shown anti-tumor efficacy in melanoma and liver cancer models in an antigen-agnostic manner.

See Ghasemi et al.

In glioblastoma, lymphatic endothelial-like cells coexist with blood endothelial cells in the brain parenchyma and promote cancer stem cell growth via altered metabolism, providing a therapeutic vulnerability for this deadly disease.

See Zhao et al.